ScreenerHero

ALGSAligos Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · aligos.com
6.670USD-3.19%Mkt Cap: 41.65M $P/E: —

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap41.65M $
Enterprise Value13.34M $
Revenue (TTM)31.52M $
Gross Profit-56.86M $
Net Income (TTM)-24.19M $
Revenue/Share3.030 USD
Last Price6.670 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees82
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS01626L1052
Valuation
P/E (Trailing)—
P/E (Forward)-1.27
PEG—
EV/EBITDA-0.17
EV/Revenue0.42
P/S1.28
P/B1.26
EPS (TTM)-7.16
EPS (Forward)-5.05
52W Range
3.98028% of range13.69
52W High13.69 USD
52W Low3.980 USD
Profitability
Gross Margin-180.40%
Oper. Margin-6.80%
EBITDA Margin-247.21%
Profit Margin-1106.72%
ROE-45.18%
ROA-27.33%
Growth
Revenue Growth2778.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-82.50M $
CapEx (TTM)437.00K $
FCF Margin-194.78%
FCF Yield-147.39%
Net Debt-26.88M $
Net Debt/EBITDA0.34
Balance Sheet
Debt/Equity0.10
Current Ratio2.19
Quick Ratio2.05
Book Value/Sh5.112 USD
Cash/Share4.865 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateAug 19, 2024
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)56.29 USD
Upside (mean)+743.9%
Target Range20.00 USD – 175.00 USD
$20.00+743.9% to mean$175.00
# Analysts7
Ownership
Shares Out.5.44M
Float3.70M
Insiders10.64%
Institutions45.65%
Short Interest
Short Ratio2.2d
Short % Float11.45%
Short % Out.9.72%
Shares Short606.52K
Short (prev mo.)543.34K
Technical
SMA 505.633 (+18.4%)
SMA 2007.157 (-6.8%)
Beta2.28
S&P 52W Chg18.16%
Avg Vol (30d)134.71K
Avg Vol (10d)184.25K
Technical Indicators
RSI (14)59.1
MACD0.4318
MACD Signal0.2714
MACD Hist.+0.1604
BB Upper8.087 USD
BB Middle5.541 USD
BB Lower2.995 USD
BB Width91.90%
ATR (14)0.5854 USD
Vol Ratio (20d)0.34x